449 related articles for article (PubMed ID: 16981801)
41. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
42. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Tanjong Ghogomu E; Tugwell P
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007848. PubMed ID: 19821440
[TBL] [Abstract][Full Text] [Related]
43. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
44. [Effectiveness of TNF antagonists in routine clinical practice and costs].
Prokes M
Vnitr Lek; 2009 Jan; 55(1):45-53. PubMed ID: 19227955
[TBL] [Abstract][Full Text] [Related]
45. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
[TBL] [Abstract][Full Text] [Related]
46. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
47. The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis.
Incerti D; Hernandez EJM; Tkacz J; Jansen JP; Collier D; Gharaibeh M; Moore-Schiltz L; Stolshek BS
J Manag Care Spec Pharm; 2020 Oct; 26(10):1236-1242. PubMed ID: 32996384
[TBL] [Abstract][Full Text] [Related]
48. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
49. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
Kobelt G; Eberhardt K; Geborek P
Ann Rheum Dis; 2004 Jan; 63(1):4-10. PubMed ID: 14672883
[TBL] [Abstract][Full Text] [Related]
50. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis.
Hazlewood GS; Barnabe C; Tomlinson G; Marshall D; Devoe D; Bombardier C
BMJ; 2016 Apr; 353():i1777. PubMed ID: 27102806
[TBL] [Abstract][Full Text] [Related]
51. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M
Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998
[TBL] [Abstract][Full Text] [Related]
52. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
53. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
54. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.
Wailoo AJ; Bansback N; Brennan A; Michaud K; Nixon RM; Wolfe F
Arthritis Rheum; 2008 Apr; 58(4):939-46. PubMed ID: 18383356
[TBL] [Abstract][Full Text] [Related]
55. Cost per responder of TNF-α therapies in Germany.
Gissel C; Repp H
Clin Rheumatol; 2013 Dec; 32(12):1805-9. PubMed ID: 23877487
[TBL] [Abstract][Full Text] [Related]
56. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.
Wisłowska M; Jakubicz D
Rheumatol Int; 2007 May; 27(7):641-7. PubMed ID: 17235556
[TBL] [Abstract][Full Text] [Related]
57. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
58. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.
Fidder HH; Singendonk MM; van der Have M; Oldenburg B; van Oijen MG
World J Gastroenterol; 2013 Jul; 19(27):4344-50. PubMed ID: 23885145
[TBL] [Abstract][Full Text] [Related]
59. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.
Neovius M; Arkema EV; Olsson H; Eriksson JK; Kristensen LE; Simard JF; Askling J;
Ann Rheum Dis; 2015 Feb; 74(2):354-60. PubMed ID: 24285495
[TBL] [Abstract][Full Text] [Related]
60. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
